title: Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
abstract: The development of alcohol dependence is associated with significant morbidity and mortality. For the majority of affected people the most appropriate goal, in terms of drinking behaviour, is abstinence from alcohol. Psychosocial intervention is the mainstay of the treatment but adjuvant pharmacotherapy is also available and its use recommended.
  
  
  
  To provide an updated analysis of current and potential pharmacotherapeutic options for the management of alcohol dependence. In addition, factors predictive of therapeutic outcome, including compliance and pharmacogenetics, and the current barriers to treatment, including doctors' unwillingness to prescribe these agents, will be explored.
  
  
  
  Relevant papers were selected for review following extensive, language- and date-unrestricted, electronic and manual searches of the literature.
  
  
  
  Acamprosate and naltrexone have a substantial evidence base for overall efficacy, safety and cost-effectiveness while the risks associated with the use of disulfiram are well-known and can be minimised with appropriate patient selection and supervision. Acamprosate can be used safely in patients with liver disease and in those with comorbid mental health issues and co-occurring drug-related problems. A number of other agents are being investigated for potential use for this indication including: baclofen, topiramate and metadoxine.
  
  
  
  Pharmacotherapy for alcohol dependence has been shown to be moderately efficacious with few safety concerns, but it is substantially underutilised. Concerted efforts must be made to remove the barriers to treatment in order to optimise the management of people with this condition.
authors.affiliation: UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, UK.
authors.forename: E T
authors.initials: ET
authors.lastname: Goh
authors.affiliation: UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, UK.
authors.forename: M Y
authors.identifier: 0000-0001-6134-1026
authors.initials: MY
authors.lastname: Morgan
mesh_terms: D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000627:therapeutic use*; D000437:Alcoholism / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D001418:Baclofen / Q000627:therapeutic use; D004221:Disulfiram / Q000627:therapeutic use; D004338:Drug Combinations; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D009271:Naltrexone / Q000031:analogs & derivatives / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D011736:Pyridoxine / Q000627:therapeutic use; D011761:Pyrrolidonecarboxylic Acid / Q000627:therapeutic use; D013654:Taurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D000427:Alcohol Deterrents; D004338:Drug Combinations; D000077236:Topiramate; D013654:Taurine; D005632:Fructose; D009271:Naltrexone; C037845:metadoxine; D001418:Baclofen; D011736:Pyridoxine; D000077443:Acamprosate; D011761:Pyrrolidonecarboxylic Acid; C038981:nalmefene; D004221:Disulfiram